Clinical profile of methotrexate-resistant juvenile localised scleroderma.

Archive ouverte

Hardy, Juliette | Boralevi, Franck | Mallet, Stephanie | Cabrera, Natalia | Belot, Alexandre | Phan, Alice | Barbarot, Sébastien | Duriez-Lasek, Audrey | Chiaverini, Christine | Hubiche, Thomas | Mahe, Emmanuel | Begon, Edouard | Bourrat, Emmanuelle | Boccara, Olivia | Aubert, Hélène | Lerosey, Martine Grall | Droitcourt, Catherine | Piram, Maryam | Mazereeuw-Hautier, Juliette | Research Group of The French Society of Paediatric Dermatology (sdfp In French), .

Edité par CCSD ; Society for Publication of Acta Dermato-Venereologica -

International audience. Methotrexate has demonstrated its efficiency for the treatment of juvenile localized scleroderma but some patients may be resistant. The aim of our study was to define the profile of such patients. We performed an observational retrospective multicenter study between 2007 and 2016 and included all children seen in the French Paediatric Dermatology and Rheumatology departments with active localized scleroderma treated by methotrexate for a minimum of 4 months. Metho-trexate efficacy was assessed clinically and/or by imaging between the fourth to twelfth months of treatment. A total of 57 patients were included. Metho-trexate dosage ranged from 7 to 15 mg/m2/week. Only 4 patients were resistant. No common features could be identified between these 4 patients. Children with localized scleroderma are rarely resistant to metho-trexate and we did not identify a clinical profile for those resistant patients.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion